… in some RAS-mutant cancers, sensitivity to MEK inhibitors … combined MEK and PI3K inhibition
will be required to instigate or maintain a pro-apoptotic effect in KRAS-mutant colon cancer …

… dissociated from RAS and thus feedback productivity is disabled. We discovered that pathway
reactivation in RAS mutant models occurs at the level of CRAF with combination treatment …

… therapeutic target in the RAS-mutant cancers. MEK inhibitors can specifically block the
pathway and are one of the key types of drugs for the treatment of the RAS-mutant cancers. As …

… In this study of KRAS-mutant lung cancer models, combining MEK inhibition with …
additionally, studies treating RAS mutant cancer cell lines by combining MEKi with PARP …

… These studies led to the serendipitous observation that RAS mutant cell lines … MEK or ERK
inhibition. We subsequently demonstrated that MEK inhibitors (MEKis) sensitize RAS mutant …

… It is necessary to consider that: i) RAS mutants are less sensitive to the MEK inhibitors in
comparison to the BRAF mutant melanomas [14]; ii) NRAS mutants exhibit paradoxical …

… mutations in the RAS pathway respond to MEK inhibitors; however, in melanoma, this is
especially true for RAF mutant tumors … NRAS mutant melanoma cell lines are sensitive to MEK …

… of combination MEK and CDK4/6 inhibitors in RAS-mutant … the combination of palbociclib
and trametinib in KRAS-mutant … with the combination of CDK4/6 and MEK inhibitors in a …

… We reasoned that MEK inhibition could initiate a feedback loop involving RAS … combined
RAF and MEK inhibition could be effective also in other cancer types bearing KRAS mutations. …

… mutant BRAF monomers potently inhibit RAF/MEK/ERK signaling. However, in the setting of
upstream activation of RAS (eg, mutant … whose tumors contain activating mutations in BRAF. …